Study Information
Status: Active, Recruiting
Study Details
View study details on clinicaltrials.gov.
Locations
San Francisco
Clinical Trial FAQs
Information for patients and study volunteers, including frequently asked questions.
Description
A Phase 3, Multicenter, Randomized, Open-label, Parallel Group, Treatment Study to Assess the Efficacy and Safety of the Lifileucel (LN-144, Autologous Tumor Infiltrating Lymphocytes [TIL]) Regimen in Combination With Pembrolizumab Compared With Pembrolizumab Monotherapy in Participants With Untreated, Unresectable or Metastatic Melanoma.
Location: CPMC (San Francisco)
Please Contact: ClinicalResearch@sutterhealth.org about study IOV-MEL-301 (TILVANCE-301)